Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesLong-Term Debt RepaymentsNet Cash FlowNet IncomeShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Editas Medicine (EDIT) Change in Cash: 2015-2025

Historic Change in Cash for Editas Medicine (EDIT) over the last 11 years, with Sep 2025 value amounting to $25.9 million.

  • Editas Medicine's Change in Cash fell 17.50% to $25.9 million in Q3 2025 from the same period last year, while for Sep 2025 it was $68.6 million, marking a year-over-year increase of 416.09%. This contributed to the annual value of $7.9 million for FY2024, which is 144.15% up from last year.
  • Per Editas Medicine's latest filing, its Change in Cash stood at $25.9 million for Q3 2025, which was up 17,366.00% from -$150,000 recorded in Q2 2025.
  • Editas Medicine's 5-year Change in Cash high stood at $215.2 million for Q1 2021, and its period low was -$138.3 million during Q3 2023.
  • For the 3-year period, Editas Medicine's Change in Cash averaged around $2.1 million, with its median value being $7.2 million (2025).
  • In the last 5 years, Editas Medicine's Change in Cash skyrocketed by 4,804.61% in 2021 and then crashed by 434.79% in 2023.
  • Quarterly analysis of 5 years shows Editas Medicine's Change in Cash stood at -$56.4 million in 2021, then dropped by 22.74% to -$69.2 million in 2022, then surged by 159.43% to $41.1 million in 2023, then fell by 13.15% to $35.7 million in 2024, then dropped by 17.50% to $25.9 million in 2025.
  • Its Change in Cash was $25.9 million in Q3 2025, compared to -$150,000 in Q2 2025 and $7.2 million in Q1 2025.